![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC52A1 |
Gene summary for SLC52A1 |
![]() |
Gene information | Species | Human | Gene symbol | SLC52A1 | Gene ID | 55065 |
Gene name | solute carrier family 52 member 1 | |
Gene Alias | GPCR42 | |
Cytomap | 17p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006766 | UniProtAcc | Q9NWF4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55065 | SLC52A1 | ATC13 | Human | Thyroid | ATC | 2.12e-37 | 6.29e-01 | 0.34 |
55065 | SLC52A1 | ATC5 | Human | Thyroid | ATC | 5.57e-37 | 6.62e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
GO:001905835 | Thyroid | ATC | viral life cycle | 173/6293 | 317/18723 | 9.22e-15 | 5.50e-13 | 173 |
GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
GO:005170134 | Thyroid | ATC | biological process involved in interaction with host | 112/6293 | 203/18723 | 1.93e-10 | 5.76e-09 | 112 |
GO:005212633 | Thyroid | ATC | movement in host environment | 94/6293 | 175/18723 | 3.20e-08 | 6.00e-07 | 94 |
GO:004440933 | Thyroid | ATC | entry into host | 76/6293 | 151/18723 | 1.54e-05 | 1.43e-04 | 76 |
GO:004671833 | Thyroid | ATC | viral entry into host cell | 72/6293 | 144/18723 | 3.38e-05 | 2.80e-04 | 72 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC52A1 | SNV | Missense_Mutation | novel | c.155N>G | p.Ser52Cys | p.S52C | Q9NWF4 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-O2-A52N-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | novel | c.182N>T | p.Gly61Val | p.G61V | Q9NWF4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CV-5435-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
SLC52A1 | SNV | Missense_Mutation | novel | c.596N>A | p.Ala199Glu | p.A199E | Q9NWF4 | protein_coding | deleterious(0.01) | benign(0.132) | TCGA-CV-7104-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | c.1205G>A | p.Gly402Asp | p.G402D | Q9NWF4 | protein_coding | tolerated(1) | benign(0.073) | TCGA-CV-A6JN-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC52A1 | insertion | Frame_Shift_Ins | novel | c.904dupA | p.Ser302LysfsTer198 | p.S302Kfs*198 | Q9NWF4 | protein_coding | TCGA-DQ-7588-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | erbitux | PD | ||
SLC52A1 | SNV | Missense_Mutation | rs778417188 | c.928N>T | p.Arg310Cys | p.R310C | Q9NWF4 | protein_coding | tolerated(0.06) | possibly_damaging(0.829) | TCGA-B7-5816-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | rs137937212 | c.218N>T | p.Pro73Leu | p.P73L | Q9NWF4 | protein_coding | deleterious(0.02) | benign(0.009) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC52A1 | SNV | Missense_Mutation | c.691N>T | p.Pro231Ser | p.P231S | Q9NWF4 | protein_coding | tolerated(0.49) | benign(0) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC52A1 | SNV | Missense_Mutation | c.292C>A | p.Leu98Met | p.L98M | Q9NWF4 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-BR-8591-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |